Nasdaq Hook News Today

Hookipa Pharma (NASDAQ:HOOK – Get Free Report) had its price target lowered by research analysts at HC Wainwright from $6.50 to $5.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm presently has a “buy” rating on the stock. Separately, Royal Bank of Canada restated an “outperform” rating and […]

Hookipa Pharma (NASDAQ:HOOK – Get Free Report) had its target price decreased by investment analysts at HC Wainwright from $6.50 to $5.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm presently has a “buy” rating on the stock. Separately, Royal Bank of Canada reaffirmed an “outperform” rating and […]

Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or...

NEW YORK and VIENNA, Austria, April 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of...

HOOKIPA announces alignment with FDA on pivotal trial design and protocol for HB-200 in combination with pembrolizumabHB-200 program receives Priority...

HOOKIPA to prioritize clinical development of HB-200 for the treatment of HPV16+ head and neck cancers and Gilead-partnered programs in infectious...

Shares of Hookipa Pharma Inc (NASDAQ:HOOK – Get Free Report) were down 16.5% during mid-day trading on Monday . The stock traded as low as $0.71 and last traded at $0.72. Approximately 9,262,100 shares were traded during trading, an increase of 749% from the average daily volume of 1,090,797 shares. The stock had previously closed […]

The stock of Hookipa Pharma Inc (NASDAQ: HOOK) has increased by 10.21 when compared to last closing price of 0.45. Despite this, the company has experienced a 18.69% gain in its stock price over the last five trading sessions. GlobeNewsWire reported 2023-11-02 that NEW YORK and VIENNA, Austria, Nov.

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line...

Royal Bank of Canada reiterated their outperform rating on shares of Hookipa Pharma (NASDAQ:HOOK – Free Report) in a research report released on Wednesday morning, Benzinga reports. Royal Bank of Canada currently has a $7.00 target price on the stock. Several other equities research analysts have also issued reports on HOOK. HC Wainwright lowered their […]